Thiogenesis Therapeutics Corp

Thiogenesis Therapeutics Corp

0.62
CAD
+0.08
(+14.81%)
-0.12EPS
Nov 24Next Earn

Important Dates

Thiogenesis Therapeutics Corp's next confirmed earnings release is scheduled for November 24, 2026.

Earnings Date11/24/2026

Share Statistics

As of June 30, 2026, Thiogenesis Therapeutics Corp has 69.98M shares outstanding.

Shares Outstanding69.98M

Financial Position

As of June 30, 2026, Thiogenesis Therapeutics Corp maintains a current ratio of 10.81, meaning it holds 10.8x the short-term assets needed to cover near-term liabilities.

Current Ratio10.81
Quick Ratio10.69

Financial Efficiency

Over the twelve months ended June 30, 2026, Thiogenesis Therapeutics Corp posted a negative return on equity (ROE) of -181.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -139.41, reflecting losses generated across the asset base.

Return on Equity (ROE)-181.53
Return on Assets (ROA)-139.41

Stock Price Statistics

As of the close on October 30, 2026, Thiogenesis Therapeutics Corp's stock has gained approximately 14.81% over the past 52 weeks.

52-Week Price Change14.81%

Income Statement

CAD

Over the twelve months ended June 30, 2026, Thiogenesis Therapeutics Corp generated - - in revenue and converted that into -6.52M in net income, yielding earnings per share of -0.12. EBITDA reached -6.52M, while operating income came in at -6.52M.

Operating Income-6.52M
Pretax Income-6.52M
Net Income-6.52M
EBITDA-6.52M
EBIT-6.52M
Earnings Per Share (EPS)-0.12

Balance Sheet

CAD

These figures are as of June 30, 2026. Total book value stands at 6.72M, with working capital of 6.72M providing operational flexibility.

Cash & Cash Equivalents7.27M
Net Debt-7.27M
Equity (Book Value)6.72M
Book Value Per Share0.10
Working Capital6.72M

Cash Flow

CAD

Thiogenesis Therapeutics Corp produced -6.73M in operating cash flow over the twelve months ended June 30, 2026.

Operating Cash Flow-6.73M
Free Cash Flow-6.73M
FCF Per Share-0.13